Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita® DMR for Type 2 Diabetes

By
Justin.choi
-
0
14
Fractyl Health, Inc. announced the activation of the tenth clinical site in the company’s pivotal REVITA-T2Di trial taking place across the US and Europe.
[Fractyl Health, Inc.]

Sorry, but the selected Zotpress account can't be found.

Press Release